Other Product. “Other Product” shall mean any and all finished drug product formulations containing (i) any Product Candidate which is directed to any target other than HBV and selected by Purchaser pursuant to Section 1.3(a)(ii), or (ii) any derivative or variant or other modification of the foregoing.
Other Product. Acceptance of Product that is not First Order Product shall occur as follows:
Other Product. (a) [ * ].
Other Product. Other Product Commercial Milestone Event [*] Commercial Milestone Payment [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] [*] For clarity, recitations of [*] in the table immediately above refers to [*].
Other Product. The term "Other Product" shall mean any Licensed -------------- Product for use in the Field which is not an Antibody Product or a Vaccine Product.
Other Product. Licensee shall have a right of first negotiation with respect to acquiring for broadcast on the Service any television product which is not covered by this Agreement for which HEDC, Hallmark Entertainment, Inc. or any subsidiary of Hallmark Entertainment, Inc. controls the rights in the Territory during the Term, whether produced prior to or after the date of this Agreement, subject to those existing output distribution arrangements identified on Schedule "C" attached hereto.
Other Product. Distribution and Networks agree to negotiate in good faith on a product-by-product basis with respect to Networks' licensing pay television exhibition rights to any television product which does not fall under this agreement (i.e., series, documentaries and specials, etc.) and for which Distribution controls such rights during the Term. Networks acknowledges that the project "Tenth Kingdom" is specifically excluded from this agreement.
Other Product. 14 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
Other Product. 14.1 In the event that during the term of this Agreement (i) Aventis (or one of its Affiliates) signs a definitive agreement with a third party by which Aventis (or one of its Affiliates) would acquire, directly or indirectly, Control (as such term is defined below) of such third party, or by which a third party would acquire, directly or indirectly, Control of Aventis (or one of its Affiliates), and (ii) the third party (or one of its Affiliates) is the owner of or is holding license rights to patents relating to another GLP-1 receptor agonist (for the purpose of this Article 14 referred to as “Other Product”), and (iii) such Other Product, at the moment of acquiring Control, is in clinical development, is approved or is commercialized in either [***], then Aventis shall notify Zealand thereof in writing within one hundred and twenty (120) days (the “Aventis Notice”). This period, however, is reduced to sixty (60) days in the event that the Other Product is one of the primary assets of such third party. In the Aventis Notice Aventis shall confirm that it intends to divest or cease the development or the commercialization of the Other Product. If Aventis does not so notify Zealand in writing within such one hundred and twenty (120) days, or if applicable sixty (60) days, then Aventis shall be deemed to be in material breach of this Agreement. However, if Aventis has notified Zealand in writing within such one hundred and twenty (120) days, or if applicable sixty (60) days, and as long as Aventis is dedicating [***] efforts to develop and commercialize the Compound or Product and is working as expeditiously as reasonably possible towards divesting (including licensing-out) the Other Product or towards ceasing the development or the commercialization thereof, Aventis shall not be deemed to be in material breach of this Agreement. Without limiting the generality of the foregoing, Aventis shall in any event complete the divesting or cease the development or the commercialization of the Other Product, as the case may be, within twelve (12) months from Zealand’s receipt of the Aventis Notice. For the purpose of this Article 14, the term “
Other Product. In cases of (ii) and (iii) the fee shall be due thirty (30) days after invoice date of such fee.
